SESSION I – IMMUNOTHERAPY UPDATES |
|
|
Welcome and Introduction of Program Co-Chairs |
Anil Kapoor |
VIEW |
Welcome: Overview Of Program, Speakers and Meeting Objectives |
Simon Tanguay, Lori Wood |
VIEW |
Immune Checkpoint Blockers: Today and Tomorrow |
Manuela Schmidinger |
VIEW |
Decoding the Discussion Between the Immune System and Tumors: A Translator Perspective |
Réjean Lapointe |
VIEW |
|
|
|
SESSION II – CURRENT RESEARCH IN CANADA |
|
|
CKCis Update Report: Data, Recent Publications and Ongoing Research |
Naveen Basappa, Rodney Breau |
VIEW |
Renal TRACERx: Deterministic Evolutionary Trajectories Govern Primary Tumour Growth |
Samra Turajlic |
VIEW |
|
Highlights in Kidney Cancer Research in Canada |
|
|
Renal Cell Carcinoma in the Canadian Indigenous Population |
Emily Wong (McMaster) |
VIEW |
Overexpression of MIR-2355 Revealed SUSD4 as Predicted Target in VHL-Inactivated Renal Cell Carcinoma |
Sandra Turcotte (Université de Moncton) |
VIEW |
Development of a Patient Decision Aid for Complex, Localized Renal Masses |
Kristen McAlpine (University of Ottawa) |
VIEW |
Exploiting Novel Therapeutic Targets to Block Metastasis of Clear Cell Renal Cell Carcinoma |
Jan Rudzinski (University of Alberta) |
VIEW |
|
Immune Checkpoint Blockades in the Clinic: Unanswered Questions, Optimizing Use, and Patterns of Response |
Toni Choueiri |
VIEW |
|
Spotlight on KCRNC-Research Trainees |
|
|
Identification and Translation of Novel Kidney Cancer Immunotherapeutic Targets Through Genetic Screens Using the CRISPR-Cas9 System |
Keith Lawson (University of Toronto) |
VIEW |
Understanding the Attributes of Papillary Renal Cell Carcinoma Subtypes: Molecular Analysis, Biomarker Discovery and Implications to Therapy |
Rola Saleeb (St. Michael’s Hospital) |
VIEW |
Genomics Analysis with Functional Imaging of RCC Patient Derived Xenografts (PDXs) to Determine If There Are Key Genetic Mutations That Are Responsible For a Drug Resistant Phenotype. |
Matthew Lowerison (University of Western Ontario) |
VIEW |
|
Clinical Trials Update, Opportunities, and Ongoing Projects in Canada |
Christian Kollmannsberger |
VIEW |
|
|
|
LATE BREAKING CANADIAN PROJECTS |
|
|
Results from Renal Hypothermia During Partial Nephrectomy |
Ilias Cagiannos, Rodney Breau |
VIEW |
2017 CUA Follow-Up Guidelines for Resected RCC |
Wes Kassouf |
VIEW |
Kidney Cancer Canada Updates |
Stephen Andrew, Andrew Weller |
VIEW |
|
|
|
SESSION III: CLINICAL AND BIOLOGICAL GENETICS and BIOMARKERS |
|
|
Contemporary Role of Cytoreductive Nephrectomy |
Stephen Boorjian |
VIEW |
Tracking Renal Cancer Evolution Reveals Constrained Routes to Metastases |
Samra Turajlic |
VIEW |
Precision Medicine from the Renal Cancer Genome |
Yasser Riazalhosseini |
VIEW |
Emerging Biomarkers of Immune Checkpoint Markers in RCC |
Toni Choueiri |
VIEW |
|
|
|
SESSION V: MOVING FORWARD |
|
|
|
Grant Presenters: |
|
|
Identifying Prognostic and Predictive Biomarkers in Metastatic Renal-Cell Carcinoma: An Exploratory Study of the International Metastatic Renal‐Cell Carcinoma Database Consortium (IMDC) Tissue Biorepository |
Shaan Dudani |
VIEW |
The Preclinical Development of a Novel Formulation to Silence the Expression of Proteins Required for Renal Cell Carcinoma Metastasis |
Jan Krzysztof Rudzinski |
VIEW |
Surveillance of Complex Renal Cysts – The SoCRAtiC Pilot Trial |
Patrick Richard |
VIEW |
Assessing Glioma-Protein Inhibition in Sunitinib-Resistance Using a Tissue-Engineered RCC Patient Derived 3-Dimensional Model |
Ninadh D’costa |
VIEW |
Discussion and Q & A |
|
VIEW |
|
Retroperitoneal Lymph Node Dissection For Renal Cell Carcinoma: Yes, No, or Sometimes? |
Stephen Boorjian |
VIEW |
|
|
|
Group 1: Moving Forward with Clinical Genetics |
Raymond Kim, Alan So |
VIEW |
Group 2: Understanding and Improving Survivorship Issues |
Jennifer Jones, Christina Canil |
VIEW |
Group 3: Optimizing/Personalizing RCC therapy |
Georg Bjarnason, Sebastien Hotte |
VIEW |
Group 4: Advancing Diagnostic Abilities and Techniques in RCC |
Luke Lavallée, Pierre Karakewicz |
VIEW |
|
|
|
Progress Report, Grant Winners and Future Discussion |
Anil Kapoor |
VIEW |